1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk

Companion diagnostics can allow for a specific patient population to be identified which will ensure those patients who are most likely to respond are recruited for clinical trials and receive the therapy once the product is launched. Companion diagnostics can help to rationalize treatment decisions, with specifics such as accurate dosing, risks of adverse events and diagnostics being made possible through these tests. Through the use of companion diagnostics, the right treatment can be delivered to the right patient at the right time, delivering greater value and optimizing healthcare resource utilization

Oncology has been the most active arena for companion diagnostics but, as research has advanced and new diagnostics developed, applications in other therapy areas are being discovered and established

The report, “Companion Diagnostics - Streamlining drug development and advancing personalized medicine” was written to support both the biopharmaceutical and diagnostic industries better understand the current challenges involved in developing products with a companion diagnostic, as well as the opportunities that will exist in the future. Recent success stories are identified and analyzed, and insights are provided throughout the study to support pharmaceutical & diagnostic strategic planning needs.

Scope

- Overview of personalized medicine and companion diagnostics
- Advantages and challenges in the development of companion diagnostics
- Analysis of case studies
- Future outlook

Key Reasons to Purchase

- This report provides an overview of advantages offered by companion diagnostics from early clinical development through to product launch and ongoing use in the patient population
- Understand what personalized medicine and companion diagnostics are and how these are expected to change the face of disease management
- Enables you to understand some of the key challenges faced during the development of companion diagnostics and recommendations on how to overcome them
- Provides an in-depth analysis of key case studies highlighting the successful application of companion diagnostics and how this has impacted company activities
- Gain insight into which pharmaceutical companies are leading the way in the development and application of companion diagnostics while assessing the key partnerships in place with diagnostics companies driving this sector forward

Table Of Contents

Companion Diagnostics - Streamlining drug development and advancing personalized medicine
Executive summary
Methodology
Personalized medicine and companion diagnostics
Personalized medicine overview
What are biomarkers?
What are companion diagnostics?
Advantages of companion diagnostics
A more targeted patient population
Focused drug development
Rationalized treatment decisions
Pharmacoeconomic advantages
Challenges in the development of companion diagnostics
Logistical challenges
Strategic business challenges
Financial risks
Regulatory challenges
Case studies
Roche - leading the way with companion diagnostics
Biogen Idec - a diagnostic to mitigate risk
Xalkori - a sign of things to come?
A look to the future
Companion diagnostics - a prerequisite to approval?
A world beyond oncology
Companies leading the way
Appendix

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics 2017-2021: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

Cancer Diagnostics 2017-2021: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

  • $ 21100
  • Industry report
  • December 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. The report is available by country, section, market segment, and can be custom-tailored to your specific information ...

2016 Competing in the Global Enteric Disease Testing Market

2016 Competing in the Global Enteric Disease Testing Market

  • $ 11500
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7500. This new 389-page report from VPGMarketResearch.com contains 97 tables and provides analysis of the global enteric ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.